Non-small cell squamous lung carcinoma
diseaseOn this page
Also known as non-small cell squamous lung cancersquamous non-small cell lung carcinoma
Summary
Non-small cell squamous lung carcinoma (MONDO:0056806) is a cancer and 16 clinical trials. Top therapeutic interventions include tislelizumab, cemiplimab, and benmelstobart. A subtype of squamous cell lung carcinoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Classification: Cancer
- Clinical trials: 16
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | non-small cell squamous lung carcinoma |
| Mondo ID | MONDO:0056806 |
| DOID | DOID:0080521 |
| NCIT | C133254 |
| SNOMED CT | 723301009 |
| UMLS | C4509816 |
| MedGen | 1383559 |
| Is cancer (heuristic) | yes |
Also known as: non-small cell squamous lung cancer · non-small cell squamous lung carcinoma · squamous non-small cell lung carcinoma
Disease family
This is a subtype of squamous cell lung carcinoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › epithelial neoplasm › squamous cell neoplasm › squamous cell carcinoma › squamous cell lung carcinoma › non-small cell squamous lung carcinoma
Related subtypes (1): lung occult squamous cell carcinoma
Subtypes (1): adenosquamous lung carcinoma
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 16.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| PHASE2 | 6 |
| PHASE1/PHASE2 | 5 |
| PHASE1 | 2 |
| Not specified | 2 |
| PHASE3 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT05718167 | PHASE3 | UNKNOWN | TQB2450 Injection Combined With Chemotherapy Followed by Sequential Combination With Anlotinib Hydrochloride Capsule for First-line Treatment of Advanced Squamous Non-small Cell Lung Cancer. |
| NCT02955290 | PHASE1/PHASE2 | ACTIVE_NOT_RECRUITING | CIMAvax Vaccine, Nivolumab, and Pembrolizumab in Treating Patients With Advanced Non-small Cell Lung Cancer or Squamous Head and Neck Cancer |
| NCT05256290 | PHASE1/PHASE2 | ACTIVE_NOT_RECRUITING | Phase 1/2 Study of Silevertinib (BDTX-1535) in Patients With Glioblastoma or Non-Small Cell Lung Cancer With EGFR Mutations |
| NCT05613413 | PHASE2 | RECRUITING | A Pilot Phase II Study of Maintenance Cabozantinib Plus Pembrolizumab for Patients With Metastatic Squamous Non-Small Cell Lung Cancer (sqNSCLC) |
| NCT05736731 | PHASE1/PHASE2 | ACTIVE_NOT_RECRUITING | A Study to Evaluate the Safety and Efficacy of A2B530, a Logic-gated CAR T, in Participants With Solid Tumors That Express CEA and Have Lost HLA-A*02 Expression |
| NCT06051695 | PHASE1/PHASE2 | RECRUITING | A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression |
| NCT06222489 | PHASE2 | RECRUITING | Whole Body HER3 Quantification With Radiolabelled Patritumab Deruxtecan (HER3-DXd) PET/CT |
| NCT06463665 | PHASE2 | RECRUITING | Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician’s Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer |
| NCT04846452 | PHASE2 | UNKNOWN | Sintilimab, Anlotinib Hydrochloride and Platinum-Containing Dual-Agent Chemotherapy in NSCLC |
| NCT05127590 | PHASE1/PHASE2 | UNKNOWN | RBN-2397 in Combination With Pembrolizumab in Patients With SCCL |
| NCT05207904 | PHASE2 | UNKNOWN | Tislelizumab Plus Chemotherapy as First-Line Treatment for Advanced Squamous NSCLC With Brain Metastases |
| NCT05865990 | PHASE2 | COMPLETED | HER3-DXd in Breast Cancer and NSCLC Brain Metastases and Solid Tumor Leptomeningeal Disease |
| NCT05873686 | PHASE1 | RECRUITING | A Phase 1 Clinical Study of NXP900 in Subjects With Advanced Cancers |
| NCT05652868 | PHASE1 | TERMINATED | Clinical Study of Antibody-Drug Conjugate MYTX-011 in Subjects With Non-Small Cell Lung Cancer |
| NCT06037733 | Not specified | RECRUITING | Primary Tumor Radiotherapy Omitting CTV for Patients With Advanced NSCLC Responded to Immunotherapy and Chemotherapy |
| NCT06207292 | Not specified | UNKNOWN | Stereotactic Ablative Radiotherapy in Synchronous and Metachronous Oligo-Metastatic Non Small Cell Lung Cancer |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| TISLELIZUMAB | 4 | 2 |
| CEMIPLIMAB | 4 | 1 |
| BENMELSTOBART | 3 | 1 |
| CATEQUENTINIB | 3 | 1 |
| OLVIMULOGENE NANIVACIREPVEC | 3 | 1 |
| PATRITUMAB DERUXTECAN | 3 | 1 |
| ATAMPARIB | 1 | 1 |
| DERUXTECAN | 1 | 1 |
| CHEMBL3824089 | 0 | 1 |